Clinical & Experimental Cardiology
Open Access

Abstract

Correction of Oxygen-Nutrient Mismatch Might Account for the Beneficial Effect of Obeticholic Acid in NASH

Gerond Lake-Bakaar*

The Farnesoid X Receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease. Obeticholic Acid (OCA), a potent, selective FXR agonist decreases portal hypertension in animal models of cirrhosis [1,2]. The drug is also effective in the treatment of non-alcoholic steatohepatitis, NASH [3-5]. The two disparate findings might be reconciled by an effect of OCA on hepatic artery flow.

Published Date: 2022-11-04; Received Date: 2022-10-04